Health Table

It's good to invest behind regulatory shifts. The 21st Century Cures Act opened up a whole new market in health insurance. ICHRAs could become a $730 billion market opportunity in the next decade. Venteur, Thatch, Gravie, Remodel Health, Take Command

After four years of some of the most intentional and passionate work of my career, I've decided to step away from my role as Managing Partner at NEXT VENTŪRES. Throughout this journey, it's been humbling to be a voice and contributor in evolving the Next Ventures thesis into Whole Person Health, as it started off small and quickly became an amalgamation of actionable investment themes. Above all, it's been a privilege to work with our founders who are courageous warriors of innovation, disruption, and change. I am thankful for the opportunity I had to build an early-stage fund focused on critical verticals of health alongside Mel, Lance, our greater team, and remarkable LPs. For now, I remain energized and excited about what lies ahead. Over the next few months, I will be ideating, exploring, connecting, and most importantly, building. I'm forever appreciative of the support that many of you have shown over the years. Let's achieve new goals and create new memories. Dream Chasing

🌟 A Huge Milestone for LEVY Health 🌟 I am overjoyed to officially announce that we’ve raised $4.5M in funding from US VC XYZ Venture Capital, with the support of Diede van Lamoen, Matthew Brezina, Atlantic Labs and Possible Ventures. This investment is a testament to our vision and the passion behind it: women deserve better care! While the past 1.5 years haven't always been the easiest ones: a whirlwind of challenges, shifting our focus from being a European company to proudly becoming an American entity, re-building the team to excel on customer expectations and living on two continents - we've always been driven by one mission: to close the reproductive care gap! I’m incredibly proud of what we’ve built—our LEVY Fertility Code. This powerful platform offers clinical decision support and virtual care pathways that guide every step of the patient journey, from information intake and lab testing to result analysis, diagnosis, treatment recommendations, and education. Even more, it adapts to meet the unique needs of our clients, ensuring they can deliver personalized care at scale. We are beyond grateful to have incredible partners like Progyny, Inc., Boston IVF, Fertilidad Integral, and Everie trusting us on this journey. What a ride it’s been! Thank you to to our supporters, early investors and our incredible team - you all have quickly shifted gears and never stopped believing in our mission to close the #reproductive #care #gap For a more compassionate and inclusive reproductive care experience for everyone involved! The best is yet to come. 💙 #ReproductiveHealth #WomensHealth #Innovation #HealthcareTransformation #Fertility

Even though we are all in Dallas, the BHB team still covers the latest and greatest news. Resilience Lab expands into med management and SMI care and — on top of that — adds an AI platform to its systems with the acquisition of Options MD. Here's why they did it and what this changes for the company. Big s/o to Morgan Gonzales with the stellar reporting. #behavioralhealth  #mentalhealth #mergersandacquisitions #startups #venturecapital #digitalhealth https://lnkd.in/e4YEenTd

One of the most promising areas for the application of AI in medicine is scaling specialty expertise. There simply aren't enough specialist doctors to care for everyone in need. We believe AI can help. As a first step towards that goal, we worked with the amazing Google medical AI team to tune and test their conversational agent AMIE in the setting of Stanford University's Center for Inherited Cardiovascular Disease. Unlike many medical studies of LLMs, we completed our testing not with curated cases or exam questions but real-world medical data presented in exactly the way we receive it in clinic. Data was in the form of reports derived from multi-modal data sources including medical records, ecgs, stress tests, imaging tests, and genomic data. AMIE was augmented by web search and self-critique capabilities and used chain-of-reasoning strategies fine-tuned on data from just 9 typical patients. What did we find? 1. Overall, AMIE responses on diagnosis, triage and management were rated by specialty cardiologists as equivalent to or better than those of general cardiologists across 10 domains. 2. Access to AMIE's responses improved the general cardiologists' responses in almost two thirds of cases. 3. Qualitative data suggested that the AI and human approaches were highly complementary with AMIE judged thorough and sensitive and general cardiologists judged concise and specific. In conclusion, our data suggest that LLMs such as AMIE could usefully democratize subspecialty medical expertise augmenting general cardiologists' assessments of inherited cardiovascular disease patients. Paper: https://lnkd.in/gCTKD7f8 Generative podcast: https://lnkd.in/gxkZdMJ5 AMIE: https://lnkd.in/gYPV2MTV Congrats to Jack O'Sullivan MD, PhD and Tao Tu for leading the charge on this work as well as all the Stanford Department of Medicine team and the amazing team led by Alan Karthikesalingam MD PhD and Vivek Natarajan at Google

It has always been a dream of mine to start my own company. Until recently, it has been an overwhelmingly daunting task in my mind. All that changed when Claudio approached me a couple years ago with something that is not only revolutionary, but will also truly change the way we practice medicine. I am officially joining Ignite Biomedical (www.ignitebiomedical.com) as co-founder and Chief Medical Officer. We recently launched our seed round to continue development of our first Therapeutic Response Predictor (TRP). Please follow us on Facebook, Instagram, LinkedIn, and/or X. Check out our website for more info on what we do and stay tuned for more exciting announcements coming soon!

In our recent chat, Christina Farr defined today’s healthcare market in one word: weird. As “stay alive until 2025” shifts to “grow now,” boards and investors are seeking new CEOs to usher in long-term sustainability. But the weird market is complicating things. That’s why I was excited to join Chrissy, Ash Zenooz, MD, and Luba Greenwood, J.D. on the latest episode of the Second Opinion Media podcast. Listen here: https://lnkd.in/edyDpGny We discussed everything companies and candidates need to build the relationships that form successful CEO searches. Here are three key takeaways. 1) The traditional view of what makes the “right” CEO is changing. Boards need to look beyond what CEO candidates have done and where they’ve worked. A first-time CEO who understands your challenges and offers creative solutions might be a better bet than someone who’s been there and done that. 2) CEO success is a give and take. To deliver results, your next leader needs to bring adaptability, reliability, and quick decision making — an experienced executive chair, and patience to build the proper team will pay long term dividends. 3) Relationships beat transactions. Just as transactional relationships hurt healthcare, transactional CEO searches hurt companies. Finding the right leader is about understanding candidates as people: their backgrounds, thinking, and outcomes. Invest the time to build a relationship with your candidates, and do it in person. Thank you for sitting down and talking all things healthcare talent with me, Chrissy, Ash, and Luba! YouTube: https://lnkd.in/edyDpGny Spotify: https://lnkd.in/eWb6p_z2 Apple: https://lnkd.in/eEDTp4VQ

Arvind Narayanan and Sayash Kapoor's book AI Snake Oil reminded me of Epic's epic fail in sepsis prediction, but also renews the question of why health systems continue to believe the 'Epic will do it' mantra. The fact that it didn't work is fine. A lot of things don't work out of the gate. Sepsis is a leading cause of death and this was a starting point for many data science efforts. The fact that Epic was claiming high efficacy of the model when in fact it was barely better than random guesses is certainly more problematic (and we owe some gratitude to UMich for doing the validation work). What's even more unforgiveable, though, was Epic using financial incentives to drive adoption of a useless and potentially harmful prediction model. Why harmful? Well if it's not much better than random guesses then it's likely some patients were miscategorized. Did Epic know and make false claims? Or were they incompetent in their evaluations? Neither is great. This behavior would normally erode trust. But the 'Epic will do it' argument continues, as Epic continues to consume so much of IS budgets while health systems are essentially held hostage to a vendor that may do some things well, but not most things. Addressing both financial and outcome challenges in health systems will require a more informed approach to identifying best in class and a rejection of the 'Epic will do it' mindset. That's still a big hill to climb.

I’m #hiring for a seasoned Health Plan and/or Digital Health leader who's a deal and contracting wizard to partner with our Commercial teams and Internal SMEs on structuring value-aligned arrangements with our biggest, most strategic clients and partners. Know anyone who might be a good fit? Please apply if interested and refer away.